Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Amends Agreement with Malaysian Investor

NEW YORK (GenomeWeb News) – Wafergen Biosystems has amended an existing agreement with its Malaysian subsidiary and the Malaysian Technology Development Corporation to change certain rights and obligations related to certain classes of Wafergen Malaysia's stock.

MDTC is a venture capital and development firm and an investor in WaferGen Malaysia.

Among the changes disclosed in a document filed with the US Securities and Exchange agreement on Thursday, is one in which the period for MTDC to exercise its put option in respect to WaferGen Malaysia's Series A redeemable convertible preference shares was extended to April 3, 2014 from Dec. 31, 2011.

The period in which MTDC may exercise its put option with respect to WaferGen Malaysia's Series C redeemable convertible preference shares was also extended to April 3, 2014 from Dec. 20, 2011.

WaferGen will determine whether MTDC will receive cash or stock when MTDC exercises the put option in respect to the Series A redeemable convertible preference shares. If MTDC receives stock, the number of shares it receives will be determined by certain conditions, it said in its SEC filing.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.